Production (Stage)
Scinai Immunotherapeutics Ltd.
SCNI
$2.72
$0.031.12%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 4.29% | 38.28% | -- | -- | -42.02% |
| Total Depreciation and Amortization | 494.05% | 237.41% | -- | -- | 2.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 106.17% | 131.82% | -- | -- | 260.94% |
| Change in Net Operating Assets | -87.94% | -115.91% | -- | -- | -545.14% |
| Cash from Operations | 12.16% | 38.87% | -- | -- | -176.83% |
| Capital Expenditure | 100.00% | 98.41% | -- | -- | 98.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 98.41% | -- | -- | 98.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 114.29% | -195.12% | -- | -- | 37.60% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 162.86% | 43.14% | -- | -- | -65.69% |